Woolsey Pharmaceuticals Receives Positive Opinion on Orphan Drug Application from the European Medicines Agency for the Treatment of ALS with BRAVYL
PRESS RELEASE NEW YORK, NY – January 3, 2021 – Woolsey Pharmaceuticals, a repurposed therapeutics development company announced that the European Medicines Agency’s Committee for Orphan Medicinal Product has issued a positive opinion on the orphan drug application for the Company’s
Woolsey Pharmaceuticals Begins ALS Study
PRESS RELEASE NEW YORK, December 13, 2021 — Woolsey Pharmaceuticals, a clinical-stage company developing treatments for neurodegenerative diseases, today announced it commenced a study of BRAVYL in Amyoptrophic Lateral Sclerosis (ALS) patients. ALS is a progressive neurodegenerative disease that affects nerve
Woolsey Pharmaceuticals Completes Second Round of Financing
PRESS RELEASE NEW YORK, NY – October 1, 2021 – Woolsey Pharmaceuticals announced today that it completed a second round of financing of $19.7 million. Proceeds will fund operations through the completion of Phase 2a clinical studies of BRAVYL for Wandering
Woolsey Pharmaceuticals Emerges from Stealth Mode to Announce Patients Enrolled in Two New CNS Studies
PRESS RELEASE One trial seeks to reduce wandering in dementia patients; the other targets two rare, deadly neurodegenerative diseases. NEW YORK, February 18, 2021 — Woolsey Pharmaceuticals, a clinical-stage company developing treatments for neurodegenerative diseases, today announced dosing of the
Woolsey Pharmaceuticals’ Financing Is Oversubscribed; Two Board Members Named
NEW YORK, NY – March 11, 2020 – Woolsey Pharmaceuticals announced today that it completed a round of financing that will fund operations through the completion of a planned clinical study. The amount was not disclosed but the financing was substantially